Moreover, the preclinical studies with an AURKA inhibitor PHA-739358 demonstrated that this kinase antagonist has specific inhibitory effects on the growth of neuroendocrine tumor cells in cell culture and xenograft models [44], suggesting that enhanced AURKA kinase activity could be essential for the maintenance of SCNC. This evidence concerns the gene AURKA and neuroendocrine neoplasm.